Company Overview and News

 
Shire Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan

21m globenewswire
Shire Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan
SHPG SHP

 
Health Canada has authorized TAKHZYRO(TM) (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema (HAE) attacks

19h globenewswire
Health Canada has authorized TAKHZYROTM (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema (HAE) attacks
SHPG SHP DYAX

79
Deciphera Pharmaceuticals: Will This ASCO Winner Repeat At ESMO?

2018-09-20 seekingalpha
The valuation gap with larger competitor Blueprint Medicines appears enticing, even after the latter's recent decline.
DCPH TSRO SHPG BPMC AMGN MRK SPPI AGIO HRTX PFE GSK

 
SHPG / Shire Plc. 8-K (Current Report)

2018-09-19 sec.gov
Document
SHPG

20
Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myers Succeeds

2018-09-15 seekingalpha - 2
Discussion: FibroGen's anti-CTGF antibody pamrevlumab indicated in idiopathic pulmonary fibrosis (IPF) is now under Fast Track review of the FDA. The new status allows a rolling review of the marketing application of the drug. Idiopathic pulmonary fibrosis is a chronic lung disease in which the lung functions progressively decline. The disease is the most common type of interstitial lung disease (ILD) in which interstitium (i.
REDIF RDHL AZN VRCA LGNDZ SHPG VERU FGEN JNJ MRK LGNZZ LGND AVDL LGNYZ LGNXZ PFE

1
SHPG / Shire Plc. 8-K (Current Report)

2018-09-13 sec.gov - 1
Document
SHPG

 
Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease

2018-09-12 globenewswire
SHIRE GRANTED EU MARKETING AUTHORIZATION FOR VEYVONDI® [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] FOR ADULTS WITH VON WILLEBRAND DISEASE
SHPG SHP

22
Sangamo (Part V): Assessing The Prospects Of SB-913

2018-09-11 seekingalpha - 2
Cicero learned man that he was, believed in self-improvement so long as his breath lasts. He commends Socrates for learning to play the fiddle late in life and another Roman for mastering Greek when old. - Charlie Munger
SHPG GILD SGMO KITE PFE BIVV ONCE RGNX

 
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-09-10 sec.gov
UNITED STATES
SHPG

 
SHIRE ANNOUNCES THE PRICING TERMS AND INCREASE IN THE MAXIMUM TENDER AMOUNT OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES

2018-09-10 globenewswire
SHIRE ANNOUNCES THE PRICING TERMS AND INCREASE IN THE MAXIMUM TENDER AMOUNT OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES Dublin, Ireland – September 10, 2018 –Shire plc (LSE: SHP and NASDAQ: SHPG) (“Shire”), Baxalta Incorporated, a Delaware corporation and wholly-owned subsidiary of Shire (“Baxalta”), and Shire Acquisitions Investments Ireland DAC, an Irish designated activity company and wholly-owned subsidiary of Shire (“SAIIDAC” and, together with Baxalta, the “Offerors”), announced today the pricing terms of the Offerors’ previously announced cash tender offers (collectively, the “Tender Offers,” and each offer to purchase a series of notes individually, a “Tender Offer”) to purchase Baxalta’s outstanding 2.
SHPG BXLT SHP MS

21
2018 Is An Ideal Entry Point For Aurinia Pharmaceuticals

2018-09-10 seekingalpha - 4
Voclosporin is in Phase III trials for treatment of lupus nephritis (LN) and has a high probability of FDA approval based on Phase IIb data.
SHPG 524715 AUP AGN AZN SUNPHARMA AUPH ABBV ACT GSK

 
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-09-10 sec.gov
UNITED STATES
SHPG

1
SHPG / Shire Plc. 8-K (Current Report)

2018-09-06 sec.gov - 1
Document
SHPG

15
Sangamo's Gene Therapy Results

2018-09-06 seekingalpha - 1
Let the arguing commence! That's my response to the announcement this morning by Sangamo (NASDAQ:SGMO), a company that's been trying to do gene therapy in the clinic. They're not a CRISPR outfit, though - they're using an alternate technique for gene silencing, using zinc finger regions instead. Even at that level, there's more than one way to go about this. Sangamo is using zinc finger nucleases, while others are trying to get the (broadly similar) TALEN technique to work as a human therapy.
SHPG SGMO

94
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 1
Glenview Capital Management's 13F portfolio value decreased from $17.10B to $14.66B this quarter. The number of positions decreased from 52 to 49.
LOW ATHTF FLEX LBTY WBA ENL CVS HPE SHPG NWL LBTYK LILAB WMB DOW MTOR CAH DXC AET CMCSK IQV EBAY MIK TMUSP TMUS BKD CBS.WD VER CNDT GOOGL LILAK RLGY MSFT CPV MHK ENDP FB PAH TMO CCV MCK CCZ GOOG DLPH CHTR AGN DXC.WI CI ARMK HOLX CBS CSC CBS.A CMCSA FTI.WI FMC LBTYB LBTYA FDX ANTM HUM DWDP ABC V CCV.CL FDC THC APTV ANTX LILA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 82481R106